Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861). We performed a multivariate logistic analysis to demonstrate the association between early infliximab trough levels and treatment outcomes of CT-...

Full description

Bibliographic Details
Published in:	Gut and Liver
Main Authors:	Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber
Format:	Article
Language:	English
Published:	Gastroenterology Council for Gut and Liver 2023-05-01
Subjects:	ct-p13 crohn disease infliximab trough level immunogenicity
Online Access:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl220005

Similar Items

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
by: So Yoon Choi, et al.
Published: (2023-06-01)

Higher induction and maintenance infliximab trough levels are associated with radiological perianal fistula healing in pediatric patients with Crohn's disease
by: Joonhyuk Son, et al.
Published: (2025-05-01)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
by: Yiyoung Kwon, et al.
Published: (2022-09-01)

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
by: Jose M. Huguet, et al.
Published: (2022-08-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
by: So Yoon Choi, et al.
Published: (2017-01-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
by: Yoon-Zi Kim, et al.
Published: (2023-09-01)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
by: Ye Ma, et al.
Published: (2023-03-01)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
by: Kouzhu Zhu, et al.
Published: (2024-08-01)

Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
by: Yoo Min Lee, et al.
Published: (2024-05-01)

Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn’s disease who develop secondary loss of response to infliximab
by: Lin Li, et al.
Published: (2025-09-01)

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
by: Jing Feng, et al.
Published: (2022-01-01)

Infliximab
by: İlgen Ertam Sağduyu
Published: (2022-04-01)

Psoas muscle CT radiomics-based machine learning models to predict response to infliximab in patients with Crohn’s disease
by: Zhuoyan Chen, et al.
Published: (2025-12-01)

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab
by: Xuan Shi, et al.
Published: (2023-08-01)

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
by: June Hwa Bae, et al.
Published: (2024-07-01)

Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease
by: Yoon Zi Kim, et al.
Published: (2025-07-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019-07-01)

Relationship between serum total bilirubin levels and primary loss of response to Infliximab therapy in Crohn’s disease patients
by: Jingjing Liu, et al.
Published: (2025-09-01)

Therapeutic regimen of Crohn’s disease: effect of Infliximab combined with mesalazine on intestinal flora and inflammatory indexes in patients
by: Xiaoxia Xiang, et al.
Published: (2025-09-01)

A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease
by: Ziheng Peng, et al.
Published: (2023-12-01)

Tracing the historical foundations of infliximab in Crohn’s disease treatment: a cited reference analysis
by: Andy Wai Kan Yeung
Published: (2024-11-01)

Comparison Between Adalimumab and Infliximab in Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis
by: Tarek Aboursheid, et al.
Published: (2025-01-01)

Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn’s disease patients
by: Jiao Zheng, et al.
Published: (2025-06-01)

The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
by: Xinyue Hu, et al.
Published: (2024-11-01)

Development and validation of a nomogram for predicting endoscopic healing in crohn’s disease patients receiving infliximab treatment
by: Lixuan Li, et al.
Published: (2025-07-01)

Correction: Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn’s disease patients
by: Jiao Zheng, et al.
Published: (2025-07-01)

CT-based radiomics signature of visceral adipose tissue and bowel lesions for identifying patients with Crohn’s disease resistant to infliximab
by: Yangdi Wang, et al.
Published: (2024-01-01)

Case Report: Facial Malassezia folliculitis following infliximab treatment in Crohn’s disease
by: Liji Chen, et al.
Published: (2025-08-01)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
by: Marla C. Dubinsky, et al.
Published: (2023-09-01)

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study
by: Ping Zhu, et al.
Published: (2022-01-01)

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
by: Yueying Chen, et al.
Published: (2021-04-01)

The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
by: Junya Song, et al.
Published: (2024-12-01)

The efficacy of infliximab combined with partial enteral nutrition in the treatment of Crohn’s disease: a cohort study
by: Chen Huang, et al.
Published: (2025-06-01)

Toll-like Receptor Gene Polymorphisms as Predictive Biomarkers for Response to Infliximab in Japanese Patients with Crohn’s Disease
by: Jingjing Wei, et al.
Published: (2025-04-01)

Effects of infliximab biosimilar on retinal microvasculature in Crohn’s disease patients evaluated by optical coherence tomography angiography
by: Hesham M. El Mazar, et al.
Published: (2025-01-01)

Constructing models for Crohn's disease diagnosis and prediction of infliximab non-response based on angiogenesis-related genes
by: Chenwei Zheng, et al.
Published: (2024-01-01)